Cloudflare
Current partial review: 2026-09-06T17:28:36.610963+00:00 · 1 of 10 traits supported.
Historical complete review: 2026-08-05 · 9 of 10 traits. This older score is not a current score.
The last complete review found growing demand for website security and services used by software makers, backed by strong operating results.
Changed since the last full check: The August 6 Q2 release postdates the board’s August 5 last-complete review.
Revenue rose from $639.8m in Q1 to $696.1m in Q2; annual growth increased from 34% to 36%. Current RPO growth increased from 34% to 35%. Q2 operating cash was $117.6m and free cash flow $56.4m. Q2 GAAP gross margin was 71.8%, below 74.9% a year earlier. GAAP operating loss widened to $205.7m from $67.3m. Cash and securities of $4,162.8m are a balance-sheet fact, not proof of recession survival or fair valuation.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Cloudflare: 1 of 10 traits have supporting evidence in the partial current review at 2026-09-06T17:28:36.610963+00:00.
Supporting reports
What argues against it
- Revenue rose from $639.8m in Q1 to $696.1m in Q2; annual growth increased from 34% to 36%. Current RPO growth increased from 34% to 35%. Q2 operating cash was $117.6m and free cash flow $56.4m. Q2 GAAP gross margin was 71.8%, below 74.9% a year earlier. GAAP operating loss widened to $205.7m from $67.3m. Cash and securities of $4,162.8m are a balance-sheet fact, not proof of recession survival or fair valuation.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 2026-09-06T17:28:36.610963+00:00
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Rocket Lab
Current partial review: 2026-09-06T17:28:36.610963+00:00 · 1 of 10 traits supported.
Historical complete review: 2026-08-05 · 8 of 10 traits. This older score is not a current score.
The last complete review found launches, paying customers and many customer orders, while major programmes still had to grow much larger.
Changed since the last full check: The August 10 Q2 release postdates the board’s August 5 last-complete review.
Q1 revenue was $200.3m and Q2 $234.1m; backlog rose from about $2.2bn to $2.36bn. Q2 GAAP operating loss narrowed to $57.514m from $59.639m a year earlier. First-half operating cash use increased to $134.407m from $77.467m. Financing supplied $1,523.403m. Ordinary shares outstanding rose from 543.575m at December 31 to 598.180m at June 30. Large cash balances therefore do not establish self-funding growth. Neutron’s planned launch is not completed execution.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Rocket Lab: 1 of 10 traits have supporting evidence in the partial current review at 2026-09-06T17:28:36.610963+00:00.
Supporting reports
What argues against it
- Q1 revenue was $200.3m and Q2 $234.1m; backlog rose from about $2.2bn to $2.36bn. Q2 GAAP operating loss narrowed to $57.514m from $59.639m a year earlier. First-half operating cash use increased to $134.407m from $77.467m. Financing supplied $1,523.403m. Ordinary shares outstanding rose from 543.575m at December 31 to 598.180m at June 30. Large cash balances therefore do not establish self-funding growth. Neutron’s planned launch is not completed execution.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 2026-09-06T17:28:36.610963+00:00
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Tempus AI
Current partial review: 2026-09-06T17:28:36.610963+00:00 · 2 of 10 traits supported.
Historical complete review: 2026-08-05 · 8 of 10 traits. This older score is not a current score.
The last complete review found growing use of tools that help organise medical information, alongside continuing losses and the risk of customers leaving.
Changed since the last full check: The July 30 release already existed at the August 5 review. This is a substantive recheck of the original evidence, not a newly released quarter.
Q2 revenue was $382.5m, up 22%. The issuer reports oncology volume growth of 31%, versus 28% last quarter, and MRD tests of 9,000 versus 6,500. It reports FDA approval of tumor-only xT CDx and a delivered AstraZeneca model. Net income of $5.6m included $98.5m of unrealized securities gains. GAAP operating loss was $75.913m; first-half operating cash use was $80.802m. Cash and securities were $820.7m, while convertible senior notes net were $1,172.781m. The Personalis transaction was an agreement, not proof of a completed acquisition.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Tempus AI: 2 of 10 traits have supporting evidence in the partial current review at 2026-09-06T17:28:36.610963+00:00.
Supporting reports
What argues against it
- Q2 revenue was $382.5m, up 22%. The issuer reports oncology volume growth of 31%, versus 28% last quarter, and MRD tests of 9,000 versus 6,500. It reports FDA approval of tumor-only xT CDx and a delivered AstraZeneca model. Net income of $5.6m included $98.5m of unrealized securities gains. GAAP operating loss was $75.913m; first-half operating cash use was $80.802m. Cash and securities were $820.7m, while convertible senior notes net were $1,172.781m. The Personalis transaction was an agreement, not proof of a completed acquisition.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 2026-09-06T17:28:36.610963+00:00
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears
Solana
Current partial review: 2026-09-06T17:28:36.610963+00:00 · 0 of 10 traits supported.
Historical complete review: 2026-08-05 · 6 of 10 traits. This older score is not a current score.
The last complete review found an active online network and many uses, but company accounts cannot show how that activity will affect its price.
Changed since the last full check: The official status was freshly observed at 2026-09-06T17:28:36.425039+00:00. This point-in-time operational observation cannot prove long-run economics or reliability.
The official live status response reported all systems operational at the captured retrieval bracket. A point-in-time operational status does not measure long-run reliability, security, users, fees, token-holder value capture, concentration or valuation.
Historical comparison: Not shown yet because the archive has not completed the same ten checks for each historical case.
Open each saved trait
Future check: No dated forecast is active.
Open the evidence and limits
Claim: Solana: 0 of 10 traits have supporting evidence in the partial current review at 2026-09-06T17:28:36.610963+00:00.
Supporting reports
What argues against it
- The official live status response reported all systems operational at the captured retrieval bracket. A point-in-time operational status does not measure long-run reliability, security, users, fees, token-holder value capture, concentration or valuation.
- Not shown yet because the archive has not completed the same ten checks for each historical case.
- The latest source checks show specific supporting and opposing facts. The August 5 full review remains historical; missing evidence prevents a new complete score, rank or price forecast.
- Where the reports came from
- Not recorded
- Languages
- Not recorded
- How recent
- Current partial review: 2026-09-06T17:28:36.610963+00:00
- Similar earlier cases
- Not measured
How sure is OTR?
Insufficient evidenceNo confidence number is shown because source quality, independent reports, freshness, opposing evidence, earlier comparisons, time accuracy are not fully measured.
The six measured checks are multiplied together. This evidence score is not the chance a prediction will be right.
- Source quality: Not fully measured.
- Independent reports: Not fully measured.
- Freshness: Not fully measured.
- Opposing evidence: Not fully measured.
- Earlier comparisons: Not fully measured.
- Time accuracy: Not fully measured.
Where this appears